Pfizer is in a tug of war with several states that intend to use some of its drugs to carry out executions.
Biocon has resolved FDA concerns about a plant in India, setting it and Mylan up to potentially win FDA approval for the first Herceptin biosimilar.
With a U.S. saline shortage intensifying, the FDA is getting Baxter preferential treatment in having power restored to saline plants in Puerto Rico.
Here's your pharma manufacturing news of note.
B. Braun, one of three main saline suppliers, is closing a plant for maintenance, a move it acknowledges will make a bad supply situation worse.
Lupin has been trying for two years to bring its plant in Goa, India, up to FDA standards, but a new warning letter says more improvements are needed.
Cardinal Health has agreed to sell its China business to Shanghai Pharma for $557 million in cash.
Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.
With expansion projects coming to fruition at a Pfizer plant in Michigan, the company expects to hire 200 workers next year.
With its global expansion dragging on earnings, Swedens Recipharm will will close two plants in Sweden and lay off 225 workers.